Score Breakdown
Trash.
Acadia Healthcare is a deeply distressed turnaround story with existential legal risk overshadowing meaningful embedded operational value. The company's $200M+ EBITDA opportunity from maturing beds is real but will take 2-3 years to fully realize, during which time a DOJ Criminal Division investigation, SEC probe, and class action settlements could consume hundreds of millions in cash and potentially threaten Medicare/Medicaid program eligibility (70% of revenue). At 4x leverage with a negative S&P outlook, the balance sheet provides minimal cushion. While the stock appears cheap at 0.7x revenue, this discount is warranted given: (1) criminal investigation with potential for fraud charges, (2) structurally higher PLGL costs ($100M+/year) that permanently impair margins vs. historical levels, (3) Medicaid payer friction creating volume headwinds, and (4) 32% short interest creating adverse selection dynamics. The returning CEO brings credibility but faces a multi-year operational and legal cleanup. This is a stock where the downside scenarios (program exclusion, massive settlement, covenant breach) are severe enough to justify avoiding despite apparent valuation cheapness.
Overvalued.
Major red flags in SEC filings.
Buying back shares.
No data.
Running out of money.
Heavy bearish bets.
Below average.
🐻 Why Bears Hate It
The short thesis centers on structural margin compression from Professional and General Liability (PLGL) expenses, which are projected to remain a $100M–$110M annual drag through 2026 (S&P Global). Additionally, new Medicaid policies in New York and Pennsylvania restricting out-of-state travel for care are expected to create a $25M–$30M EBITDA headwind and a 350-basis-point volume drag at key specialty sites (TradingView, Simply Wall St).
🔍 What's In The SEC Filings
The company is under severe multi-agency investigation for potentially fraudulent admission and billing practices, evidenced by a massive goodwill impairment and unprecedented legal settlements.
Grand Jury Subpoena from DOJ Criminal Division
“In September 2024, the Company received a grand jury subpoena from the United States District Court for the Western District of Missouri (the “W.D.Mo.”), issued by attorneys from the Criminal Division of the U.S. Department of Justice (the “DOJ Criminal Division”)”
The investigation targets the acute care service line, focusing on illegalities regarding admissions, length of stay, and billing practices, suggesting systemic healthcare fraud.
SEC Investigation into Billing and CTC Services
“The Company has also received subpoenas from the United States Securities and Exchange Commission (“SEC”) requesting similar information as well as information relating to the CTC service line.”
The parallel SEC investigation suggests that the billing and admission issues previously identified by the DOJ may have material impacts on financial reporting and securities disclosures.
Massive Goodwill Impairment Post-Triggering Event
“This subsequent goodwill impairment analysis resulted in a non-cash goodwill impairment charge of $996.2 million, representing the amount by which the Company’s book value exceeds its fair value”
Management performed a clean impairment test on Oct 1, 2025, but was forced to write off nearly $1B by Dec 31 due to 'sustained decline in stock price' and 'higher professional and general liability expenses associated primarily with patient-related litigation.'
Unprecedented Surge in Professional Liability Claims
“The professional and general liability reserve was $181.8 million at December 31, 2025... a significant increase in claim frequency during the policy year ended August 31, 2025”
The company recorded unfavorable adjustments of $52.7 million in 2025 alone, indicating that historical actuarial assumptions are failing to capture the scope of current patient-related litigation and abuse cases.
Ill-Timed Share Repurchases Amid Criminal Probe
“During the twelve months ended December 31, 2025, the Company repurchased 1,706,625 shares of its common stock... for a total of $50.4 million”
Management spent $50M on buybacks to support the share price while simultaneously dealing with a $1B net loss and a criminal grand jury subpoena, prioritizing optics over liquidity preservation.
The intrinsic value must be heavily discounted for a 'legal overhang' penalty. Investors should model for multi-hundred million dollar fines and potential exclusion from federal health programs (Medicare/Medicaid), which currently represent over 70% of total revenue.
Management transition costs were elevated in prior years, and the current internal investigation using external advisors is likely to incur significant 'Transaction, legal and other costs' beyond the $163.6 million reported this year.
At the current burn rate, this company will need to raise money or die.